Supply of Ranitidine (as hydrochloride) (Ranoxyl) by Ascent Pharma Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted in 1989, governs the regulation of therapeutic goods in Australia. The Act was introduced to address the need for a unified and systematic approach to regulating therapeutic goods, including medicines, medical devices, and blood products, to ensure their safety, quality, and efficacy. The Therapeutic Goods Administration (TGA), an agency within the Australian Government Department of Health, is responsible for the administration and enforcement of the Act. The policy objective is to protect public health by ensuring that therapeutic goods available in Australia are of acceptable quality, performance, and safety. On September 3, 2012, the delegate of the Secretary of the Department of Health and Ageing provided consent for the supply of specific Ranitidine products by Ascent Pharma Pty Ltd, under certain conditions. This consent was granted under subsection 14 and 14A of the Therapeutic Goods Act 1989, allowing the supply of Ranitidine (as hydrochloride) products that did not conform to certain labelling requirements. The consent was specific to certain batches of the products and required that the carton labels used for these batches be identical to those provided by the company, including an over-sticker as specified by the TGA. This decision was made to ensure that the products met the necessary standards for safety and quality while allowing for the supply of these specific batches.

Scope and Application

The Therapeutic Goods Act 1989 provides a framework for the regulation of therapeutic goods in Australia, and section 14 and 14A of the Act pertain to the supply of therapeutic goods that do not conform with standards set out in Therapeutic Goods Orders. This legislation applies to entities such as Ascent Pharma Pty Ltd, which must seek consent from the Secretary of the Department of Health and Ageing if their products do not meet specified standards. The consent granted in this case is limited to specific products and batches, namely Ranitidine (as hydrochloride) (Ranoxyl) 150 mg tablet blister pack and Ranitidine (as hydrochloride) (Ranoxyl) 300 mg tablet blister pack, batches B732 and B734 respectively. The jurisdictional reach of this Act is national, as it is a Commonwealth Act, applying across all states and territories in Australia. The consent provided is subject to specific conditions, such as the use of specified carton labels and over-stickers, and does not permit any other changes to the products. The application of this Act extends to ensuring the therapeutic goods supplied are safe, of acceptable quality, and correctly labelled, thereby protecting public health.

Key Provisions

Section 14 and 14A of the Therapeutic Goods Act 1989 permit the delegate of the Secretary of the Department of Health and Ageing to give consent for the supply of therapeutic goods that do not conform to certain specifications, provided certain conditions are met. In this case, the delegate has consented to the supply of two batches of Ranitidine products by Ascent Pharma Pty Ltd, which do not conform to the specifications in Therapeutic Goods Order 69 in that the quantity of the active ingredient is expressed differently on the carton labels. This consent is subject to the conditions outlined in section 15(1) of the Act, which include that only batches B732 and B734 of the specified products can be supplied, and that the carton labels used for these batches must be identical to those provided by the company in correspondence dated August 23, 2012, and must include an over-sticker specified by the Therapeutic Goods Administration (TGA). The obligations and requirements imposed by the Act on the parties involved include ensuring that the consent is strictly adhered to, particularly in relation to the use of specified carton labels and the restriction of supply to the specified batches. Ascent Pharma Pty Ltd must ensure that the carton labels used for the relevant batches are exactly as provided in the correspondence and include the TGA over-sticker. Furthermore, only the specified batches (B732 and B734) can be supplied under this consent. Any deviation from these conditions could result in the consent being revoked, and the non-conforming products could be subject to regulatory action. The Therapeutic Goods Act 1989 outlines various offences, penalties, and consequences for breaches of its provisions. While the specific provisions related to the consent in this instance do not explicitly state penalties, general offences under the Act can lead to significant civil and criminal consequences. For example, supplying therapeutic goods that do not comply with the Act can result in substantial fines, with the maximum penalty often aligning with the severity and intent of the breach. Criminal penalties can also be imposed, including imprisonment, particularly if the breach is deemed to have caused harm or posed a significant risk to public health and safety. It is important for Ascent Pharma Pty Ltd to comply with all conditions of the consent to avoid any potential legal repercussions.